Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly?
Oral estrogens reduce GH-induced IGF-1 production and preliminary studies have shown that adjuvant estroprogestin (EP) therapy with octreotide LAR may control disease activity in some female patients who are partially responsive to octreotide LAR. Our aim was to verify if EP alone or in combination with octreotide LAR can achieve remission of acromegaly in selected cases of patients uncontrolled by surgery. Eleven women with persistent active acromegaly following surgery participated in this unblinded open label pilot study. Their mean age was 49.8 ± 4.3 years. Two patients were drug naïve, two patients had stopped octreotide LAR because of intolerance and seven were treated with octreotide LAR. The patients received either EP (EP pill, 20 μg ethinylestradiol, 100 μg levonorgestrel) alone (4 patients) or added to octreotide LAR (7 patients). Fasting GH, IGF-1, glucose, HDL- and LDL-cholesterol, and triglycerides were measured at baseline and at last visit. MRI was controlled at baseline and at last visit. Duration of estrogen treatment was 3.1 ± 0.5 years. Serum IGF-1 levels were normalized in 8/11 patients (73%). Serum GH concentrations did not change significantly during treatment (11.6 ± 5.6 μg/L prior to EP vs 5.5 ± 1.2 μg/L following EP). In patients treated with EP alone, remission was achieved in 2/4 patients (IGF-1 percentages of the upper limit of normal age-matched range (%ULN): 211 ± 40% before EP compared to 95 ± 15% after EP, P = 0.028). In the seven patients treated by EP added to octreotide LAR, remission was achieved in 6 patients (IGF-1%ULN: 158 ± 9% before EP compared to 86 ± 4% after EP, P = 0.0003). Glucose and cholesterol levels were unchanged by EP treatment (data not shown). MRI did not show any evidence of tumour progression with EP in patients who had a tumour remnant. In conclusion, oral estrogen treatment appears to normalize serum IGF-1 concentrations in over 70% of women with acromegaly uncured by surgery irrespective of their sensitivity to octreotide LAR. We suggest that estrogens may be a temporary cost-effective and safe treatment for women with postoperative persistent acromegaly.
Vallette
Sophie
S
Department of Endocrinology, Centre Hospitalier de l'Université de Montréal, Notre-Dame Hospital, Université de Montréal, 1560 Sherbrooke East, Montreal, QC, Canada.
Serri
Omar
O
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D000284:Administration, Oral; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D001786:Blood Glucose / Q000187:drug effects; D004338:Drug Combinations; D004358:Drug Therapy / Q000191:economics* / Q000379:methods; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015282:Octreotide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D001786:Blood Glucose; D004338:Drug Combinations; D008055:Lipids; D009652:Norpregnenes; C494367:estroprogestin; D004997:Ethinyl Estradiol; D007334:Insulin-Like Growth Factor I; D015282:Octreotide